Logo 202


MiNDERA is developing a microneedle platform that leverages genomic science to enable a new era of skin analytics through personalized treatment decisions.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location South San Francisco, CA, USA
  • Currency USD
  • Founded December 2013
  • Employees 3
  • Incorporation Type C-corp
  • Website

Company Summary

MiNDERA is a predictive health/precision medicine company that leverages never before available data to enable better patient outcomes in skin conditions. Our first product is in psoriasis, where using our microneedle platform allows for faster/more appropriate treatment, saving the system money while giving patients better outcomes & allowing partnered companies to gain market share for their treatments.


  • 35e0810d c921 43f1 8451 70eb4f264e24
    President, CSO, & Co-Founder

    -Associate Professor TSRI Department of Chemistry and Worm Institute for Research and Medicine 2005-present
    -BS Chemistry with high honors 1999 UVa
    -MA Chemistry 2000 UVa
    -PhD Chemical Biology 2004 TSRI
    -Scientific expertise includes diagnostic platform development, small molecule & vaccine discovery, metabolomics, scientific algorithm & software development, phage display, & neglected tropical diseases.

  • Default avatar
    Tahir Mahmood
    Co-founder and Director

    -CEO and Co-founder at Applied Molecular Transport, a biotech developing next generation biotherapeutics for treating immune-mediated inflammation and metabolic diseases
    -Previously led the US West Coast Life Sciences practice at Booz Allen Hamilton and was Managing Director at Lake Sherwood Partners
    -Visiting Investigator at TSRI
    -Principal Business Analyst at Amgen, supporting BD, M&A and strategic venture fund transactions

Previous Investors